A recombinant anti-VEGF humanized monoclonal antibody Fab fragment injection approved to conduct a clinical trial.
Our CEO Delivers Speech on Antibody R&D.
Coming events this November. Welcome!
JECHO focuses on high-end biopharmaceuticals, including monoclonal antibodies, recombinant proteins, oncolytic viruses, immunotoxins, vaccines, etc.
Our businesses cover the entire industrial chain of biopharmaceutical delivery, such as research and development, production and launch, which depends on our strong technology innovation, top-sourced equipments and well-designed facilities, GMP-compliant process management system, and most importantly, the growing team of excellent employees.
While committed to making technology innovation in medicine for achieving success, JECHO also actively engage in win-win cooperation with global customers, providing high-quality products, value-added services as well as complete solutions.